09-May-2019 | Zion Market Research
Zion Market Research has published a new report titled “Liquid Biopsy Market by Target Analyte (Circulating Tumor Cells (Ctcs), Circulating Tumor DNA (CtDNA), Exosomes, Nucleosomes, and Other Biomarkers), by Analytical (Molecular, Proteomic, and Histology/Imaging), by Application (Routine Screening, Patient Work-Up, Early-Stage Disease, and Late-Stage/Metastatic Disease), by Cancer Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Brain Cancer, and Others), by Sample (Blood, Urine, and Others), and by End-User (Hospitals, Research Laboratories, Academia, and Research Centers): Global Industry Perspective Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, global liquid biopsy market was valued at around USD 1,244 million in 2018 and is expected to generate approximately USD 12,062 million by 2025, at a CAGR of slightly above 38.3% between 2019 and 2025.
A biopsy is a tissue or cell sample taken from any part of the human body, which is sent to the lab for examining various disease types. A liquid biopsy is an advanced form of treatment procedure for cancer, wherein bodily fluids like blood or urine are collected for disease detection. A liquid biopsy helps in planning treatment regime along with finding out effective treatment options for the patients. The global liquid biopsy market growth can be attributed to the increasing incidences of cancer, growing demand for minimally invasive surgeries and personalized medicine, and rising healthcare expenditure.
Browse the full “Liquid Biopsy Market by Target Analyte (Circulating Tumor Cells (Ctcs), Circulating Tumor DNA (CtDNA), Exosomes, Nucleosomes, and Other Biomarkers), by Analytical (Molecular, Proteomic, and Histology/Imaging), by Application (Routine Screening, Patient Work-Up, Early-Stage Disease, and Late-Stage/Metastatic Disease), by Cancer Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Brain Cancer, and Others), by Sample (Blood, Urine, and Others), and by End-User (Hospitals, Research Laboratories, Academia, and Research Centers): Global Industry Perspective Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/global-liquid-biopsy-market
The global liquid biopsy market is fragmented on the basis of target analyte, analytical, cancer type, sample, and end-user. The target analyte segment includes circulating tumor cells, circulating tumor DNA, exosomes, nucleosomes, and other biomarkers. The analytical segment includes molecular, proteomic, and histology/imaging. The molecular analytic segment holds the largest market share due to the increasing number of liquid biopsy on cancer patients. By cancer type, the market includes breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. Colorectal and prostate cancers held the largest market shares in 2018 due to the high incidences among the Asia Pacific population. The sample segment includes urine, blood, and others. The blood segment holds the largest share as it is the commonly used sample extract by most of the doctors and specialist physicians for oncology examination. The end-user segment includes hospital, research laboratories, academia, and research centers.
The liquid biopsy market in the Asia Pacific region is estimated to show the highest CAGR over the forecast time period, owing to the rising cancer incidences, growing aging population, increasing privatization and deregulation within the healthcare sector, and provisional financing of health services across the region. Japan, Singapore, Australia, and the Republic of Korea remain key regional investors for liquid biopsy. Additionally, the global market will witness significant demand from developing economies like India and China. North America and Europe are considered to be the foremost regions for liquid biopsy market in terms of revenue, due to the increasing R&D expenditure, clarity in the regulatory process, growing demand for minimally invasive surgeries, and high expenditure related to healthcare.
Some major players in the global liquid biopsy market include Biocept, Cynvenio, NeoGenomics Laboratories, Qiagen, Trovagene, RainDance Technologies, Guardant Health, Exosome Diagnostics, SAGA Diagnostics AB, Circulogene Theranostics, Inivata, Agena Bioscience, Admeria Health Personal Genome Diagnostics, and Adaptive Biotechnologies.
This report segments the global liquid biopsy market into:
Global Liquid Biopsy Market: Target Analyte Analysis
Global Liquid Biopsy Market: Analytical Analysis
Global Liquid Biopsy Market: Application Analysis
Global Liquid Biopsy Market: Sample Analysis
Global Liquid Biopsy Market: Cancer Type Analysis
Global Liquid Biopsy Market: End-User Analysis
Global Liquid Biopsy Market: Regional Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651